Pregled bibliografske jedinice broj: 1032395
Smoothened protein expression and promoter methylation status in serous ovarian carcinomas
Smoothened protein expression and promoter methylation status in serous ovarian carcinomas // International journal of gynecologic cancer, 29 (2019), Suppl 4
Atena, Grčka, 2019. A495 (EP923), 1 doi:10.1136/ijgc-2019-ESGO.969 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1032395 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Smoothened protein expression and promoter methylation status in serous ovarian carcinomas
(Smoothened protein expression and promoter
methylation status in serous ovarian carcinomas)
Autori
Mioč, Pavao ; Karin Kujundžić, Valentina ; Matijević, Ratko ; Škrtić, Anita ; Vranić, Semir ; Šerman, Ljiljana
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
International journal of gynecologic cancer, 29 (2019), Suppl 4
/ - , 2019
Skup
21st European congress on gynaecological oncology
Mjesto i datum
Atena, Grčka, 02.11.2019. - 05.11.2019
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Hedgehog signaling pathway ; smoothened ; serous ovarian carcinomas
Sažetak
Aberrant Hedgehog (Hh) pathway signaling has been implicated in pathogenesis of several human cancers. Recent studies have indicated its active role in serous ovarian carcinomas. Smoothened protein (SMO), a transmembrane co-receptor in Hh pathway signal transduction, is inhibited in non- dividing cells, thus its disinhibition might be a trigger for uncontrolled cell proliferation and growth. Very few studies have explored the role of SMO in serous ovarian cancers. The aim of the study was to assess the expression of SMO protein and to explore the Smoothened gene promoter methylation in a cohort of serous ovarian carcinomas. SMO protein expression was immunohistochemically quantified in 40 high-grade serous carcinomas (HGSC), 12 low-grade serous carcinomas (LGSC), 20 normal ovarian and 9 normal fallopian tube samples (controls). SMO gene promoter methylation status was analyzed using methylation-specific polymerase chain reaction (MSP) in randomly selected HGSCs (n=10), LGSCs (n=10), and normal fallopian tube (n=9) samples. Kaplan-Meier survival plots were used to estimate the impact of SMO expression on patients‘ overall survival (OS). SMO nuclear expression was significantly higher in HGSCs and LGSCs compared with the fallopian tube samples (p=0.010 and p=0.003, respectively). LGSCs, compared with normal ovarian tissue, exhibited higher total, cytoplasmic/membrane and nuclear expression (p=0.000, p=0.001 and p=0.000, respectively). Comparing HGSCs and LGSCs, significantly higher total and cytoplasmic/membrane expression was found in HGSC (p=0.026 and p=0.030, respectively). SMO gene promoter was unmethylated in both LGSCs and HGSCs as well as in fallopian tube. In addition, the SMO protein expression had no significant impact on patients‘ OS (p=0.07). Our data indicate the lack of SMO gene promoter methylation while a significant overexpression (particularly nuclear) of SMO protein characterized a substantial proportion of serous ovarian carcinomas. Further functional studies should elucidate the clinical relevance of these findings.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinička bolnica "Merkur",
Medicinski fakultet, Zagreb
Profili:
Anita Škrtić
(autor)
Ljiljana Šerman
(autor)
Ratko Matijević
(autor)
Valentina Karin Kujundžić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE